scholarly journals Inhaled Nitric Oxide in Patients With Pulmonary Hypertension Due to Valvular Heart Disease and Chronic Lung Disease

1998 ◽  
Vol 62 (12) ◽  
pp. 877-882
Author(s):  
Michiko Sakane ◽  
Toshiyuki Ishimitsu ◽  
Hiroki Ninomiya ◽  
Itaru Ohtsu ◽  
Toshihiko Saito ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Valvular Heart Disease ◽  
Inhaled Nitric Oxide

scholarly journals 232 Treatment of Chronic Lung Disease Associated Pulmonary Hypertension with Inhaled Nitric Oxide Administered via Nasal Cpap

2004 ◽  
Vol 56 (3) ◽  
pp. 503-503 ◽  
Author(s):  
F Sandri ◽  
G Ancora ◽  
G Bronzetti ◽  
M G Capretti ◽  
R Sciutti ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Inhaled Nitric Oxide ◽  
Nasal Cpap

scholarly journals Surfactant Composition and Function in a Primate Model of Infant Chronic Lung Disease: Effects of Inhaled Nitric Oxide

2006 ◽  
Vol 59 (1) ◽  
pp. 157-162 ◽  
Author(s):  
Philip L Ballard ◽  
Linda W Gonzales ◽  
Rodolfo I Godinez ◽  
Marye H Godinez ◽  
Rashmin C Savani ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Inhaled Nitric Oxide ◽  
Primate Model ◽  
Surfactant Composition ◽  
And Function

Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease*

2009 ◽  
Vol 37 (3) ◽  
pp. 980-986 ◽  
Author(s):  
Ning Yin ◽  
Stephanie Kaestle ◽  
Jun Yin ◽  
Thomas Hentschel ◽  
Axel R. Pries ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Inhaled Nitric Oxide ◽  
Left Heart ◽  
Left Heart Disease

Inhaled nitric oxide in infants with developing or established chronic lung disease

1995 ◽  
Vol 84 (10) ◽  
pp. 1188-1192 ◽  
Author(s):  
PA Lonnqvist ◽  
B Jonsson ◽  
P Winberg ◽  
CG Frostell
Keyword(s):  
Nitric Oxide ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Inhaled Nitric Oxide

Abstract 17912: Importance of Acute Hemodynamic Effects of Inhaled Nitric Oxide in Optimization of Heart Failure Treatment in Patients with Pulmonary Hypertension due to Left Heart Disease

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Shunsuke Tatebe ◽  
Koichiro Sugimura ◽  
Kotaro Nochioka ◽  
Tatsuo Aoki ◽  
Masanobu Miura ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Arterial Pressure ◽  
Vascular Resistance ◽  
Inhaled Nitric Oxide ◽  
Left Heart ◽  
Hemodynamic Effects ◽  
Left Heart Disease

Background: Pulmonary hypertension (PH) due to left heart disease (LHD) is a major category of the disorder. We have recently reported that elevated pulmonary vascular resistance (PVR) in patients with post-capillary PH (pc-PH: defined as mean pulmonary arterial pressure (mPAP)≥25mmHg and pulmonary capillary wedge pressure (PCWP)>15mmHg) is associated with poor prognosis compared with those with no PH or pc-PH without elevated PVR. Although new treatment is required for targeting pulmonary vascular disease (PVD), thereis a concern about raising PCWP. In this study, we thus examined acute hemodynamic effects of inhaled nitric oxide (iNO) in patients with PH due to LHD and whether optimal heart failure (HF) treatment ameliorates pc-PH. Methods: We examined 60 consecutive pc-PH patients with chronic heart failure (63±14[SD] years, M/F 38/22, NYHA≥2) who underwent acute vasoreactivity test by iNO (40 ppm for 10 min) under right heart catheterization at our hospital from June 2011 to May 2014. Among them, 25 had valvular heart disease (VHD) and 35 had non-VHD. PVD (defined as PVR> 240dynes/s/cm -5 ) was noted in 18. We also evaluated right ventricular systolic pressure (RVSP) by echocardiography after optimization of HF treatment such as medications and valvular surgery. Results: iNO significantly decreased mPAP (-1.7±0.5 mmHg; P<0.01) and PVR (-66 ±14dyne/s/cm -5 , P<0.01) without altering cardiac output. iNO significantly increased PCWP (1.3±0.5 mmHg, P=0.01) only in non-VHD patients, while it significantly increased mean arterial pressure and systemic vascular resistance in VHD patients than in non-VHD patients (both P<0.05). Pc-PH patients with PVD were re-classified as having pc-PH without PVD in 9 and no PH in 1. Eight patients remained pc-PH with PVD. After the optimal medical treatment for 7.6 months, RVSP was significantly decreased in both non-VHD and VHD patient (-8±3mmHg, P=0.04, -19±8mmHg, P=0.01, respectively). However, in non-VHD group, significant reduction in RVSP was noted only in pc-PH patients without PVD (-8±3mmHg, P=0.03). Conclusions: These results indicate that elevated PVR in patients with pc-PH and non-VHD could be a novel therapeutic indication for NO-related pulmonary vasodilators in the current practice of HF.

Sign in / Sign up

Export Citation Format

Share Document